Friday, September 17, 2021 3:04:53 PM
Interesting how many don't understand the format, temper, and purpose of scientific papers. With the scientific method, most scientists (doctors are actually scientists of sorts also) make interventions and observations. They don't control 100% of the process because there are too many external and uncontrollable influences - it's just a fact of the world we live in.
You can think it as their educated observations. That's why people rely upon well educated and experienced scientists to further our knowledge of our surroundings. The quest for knowledge is what separates us from smooth brained apes.
So, when scientists document their actions, interventions, and observations there is always a VERY remote chance that something that they didn't take into account was a contributing factor. However, when multiple scientists in multiple locations take a previously documented study and attempt to replicate it...to either reinforce the findings or refute them....This is part of the "peer review" process which helps steer if something is worthy of pursuing or it's unrepeatable and not valid.
As far as my readings of hundreds of scientific papers that deal with the immune system and how it relates to leronlimab, I find recurring themes - that the drug shows significant and newfound treatment possibilities. We are literally watching the evolutionary discovery of treatments that will revolutionize medicine as we've known it. But I'd offer to say that I am a mere novice compared to CTMedic and Ohm20's understanding and comprehension level.
And for those challenged in understanding and patience there's this.....
TL;DR: Everyone needs to brush up on legal understanding of someone’s opinion and the fact that statements made in a scientific publication can’t be opinions. We'll leave that for anonymous message boards and Op-Eds.
You can think it as their educated observations. That's why people rely upon well educated and experienced scientists to further our knowledge of our surroundings. The quest for knowledge is what separates us from smooth brained apes.
So, when scientists document their actions, interventions, and observations there is always a VERY remote chance that something that they didn't take into account was a contributing factor. However, when multiple scientists in multiple locations take a previously documented study and attempt to replicate it...to either reinforce the findings or refute them....This is part of the "peer review" process which helps steer if something is worthy of pursuing or it's unrepeatable and not valid.
As far as my readings of hundreds of scientific papers that deal with the immune system and how it relates to leronlimab, I find recurring themes - that the drug shows significant and newfound treatment possibilities. We are literally watching the evolutionary discovery of treatments that will revolutionize medicine as we've known it. But I'd offer to say that I am a mere novice compared to CTMedic and Ohm20's understanding and comprehension level.
And for those challenged in understanding and patience there's this.....
TL;DR: Everyone needs to brush up on legal understanding of someone’s opinion and the fact that statements made in a scientific publication can’t be opinions. We'll leave that for anonymous message boards and Op-Eds.
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM

